Article information
Full text is only aviable in PDF
Bibliografia
[1.]
M. Black, J. Mitchell, K. Zimmerman, G. Epler.
Isoniazid associated hepatitis.
Gastroenterol, 69 (1975), pp. 289-292
[2.]
P. Blanchon, J. Paillas, B. Blanchon, Y. Groseille, F. Blanchon.
Les icters mortels des traitements antituberculeux comportant de la rifampicine.
Rev Fr Mal Resp, 1 (1973), pp. 1135-1138
[3.]
British Thoracic Association.
A controlled trial of 6 month chemotherapy in pulmonary tuberculosis.
Br J Dis Chest, 75 (1981), pp. 141-143
[4.]
G. Decroix, et al.
Etude coraparative du traitement de la tuberculose pulmonaire par l’association de rifampicine et isoniazide administrées cotidiennement et deux fois par semaine pendant une année.
Rev Tuberc Pneumol, 35 (1971), pp. 39-42
[5.]
J. Emerit, G. Decroix, G. Chomette, C. Perie, D. Pessayre.
Données nouvelles sur les hépatites observées au cours des traitements antituberculeux incluant la rifampicine.
Rev Fr Mal Resp, 2 (1974), pp. 565-566
[6.]
D. Girling.
Adverse reactions to rifampicin in antituberculosis regimens.
J Antimicr Chemoth, 3 (1977), pp. 115-117
[7.]
D. Girling.
La hepatitis y otras reacciones secundarias de la quimioterapia antituberculosa.
Bol Un Intern Tuberc, 55 (1980), pp. 9-14
[8.]
C. Grassi, L. Mainaldo, et al.
Funzionalita epatica e farmaci antitubercolari.
Giorn Ital Chemot, 20 (1973), pp. 1-5
[9.]
C. Gronhagen-Riska, P. Hellstrom, B. Froseth.
Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis.
Am Rev Respir Dis, 118 (1978), pp. 461
[10.]
D. Kopanoff, D. Snider, G. Casas.
Isoniazid related hepatitis. A US Public Health Service Cooperative Surveillance Study.
Am Rev Respir Dis, 117 (1978), pp. 991-994
[11.]
G. Lalevée, Y. Zein, A. Llorens.
La tolérance hépatodigestive des antibiotiques antituberculeux.
Rev Fr Mal Resp, 7 (1979), pp. 483-484
[12.]
R. Lesobre, J. Ruffino, L. Teyssier, F. Achard, G. Préfort.
Les icters au cours du traitement par la rifampicine.
Rev Tuberc Pneumol, 33 (1969), pp. 393-394
[13.]
R. Newman, et al.
Rifampin in initial treatment of pulmonary tuberculosis.
Am Rev Respir Dis, 109 (1974), pp. 216-219
[14.]
G. Porven, R. Goldberg, R. González, A. Angelelli, L. Koss, J. Vilella, S. Kohan.
Investigación del antígeno Australia en 357 enfermos tuberculosos bacteriológicamente confirmados.
Arch Arg Tisiol Neumon, 50 (1981), pp. 22-24
[15.]
P. Scheuer, J. Summerfield, S. Lal, S. Sherlock.
Rifampin hepatitis.
Lancet, 1 (1974), pp. 421
[16.]
D. Baron, J. Bell.
Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or PAS, plus isoniazid and streptomycin.
Tubercle, 55 (1974), pp. 115-118
[17.]
J. Mitchell, H. Zimmerman, M. Black.
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites.
Clin Pharmac Ther, 18 (1975), pp. 26-28
[18.]
G. Ellard, D. Mitchison, D. Girling, A. Nunn, W. Fox.
The hepatotoxicity of isoniazid among rapid and slow acetylators of the drugs.
Amer Rev Respir Dis, 118 (1978), pp. 628-629
[19.]
J.A. Pilheu, M.C. De Salvo, O.R. Koch.
Esquemas antituberculosos con pirazinamida. Su acción sobre el hígado.
Rev IBIT (Brasil), 39 (1980), pp. 69-70
[21.]
M.C. De Salvo, A.S. Yunis, E. Basbus.
Tuberculosis hepática.
Rev Arg Tuberc Enf Pulm, 40 (1979), pp. 45-47
[22.]
C.R. Duncan, J.C. D’Auría, A. Sundblad.
Tuberculosis hepática.
Medicina (Buenos Aires), 33 (1973), pp. 716-719
[23.]
V. Pérez, et al.
Enfermedades del hígado.
El Ateneo, (1982),
[24.]
D. Greenblatt, F. Sellers, R. Shader.
Drug disposition in old age.
N Engl J Med, 306 (1982), pp. 1081-1083
[25.]
J. Ouslander.
Drug therapy in the elderly.
An Intern Med, 95 (1982), pp. 711-712
[26.]
Pilheu JA, Moro A, Vasini R, Wolff C, Cinto R. Concentración de rifampicina sérica en los tuberculosos de edad avanzada. XXV Conf Mund Tuberc Enf Pulm. Buenos Aires, 15-18/XII/1982 (en prensa).
[27.]
H. Thomas, D. Jewell.
Clinical gastrointestinal immunology.
Blackwell Scientific Pub, (1979), pp. 49
Copyright © 1986. Sociedad Española de Neumología y Cirugía Torácica
